Compounds > dabigatran
Page last updated: 2024-09-05

dabigatran and zithromax

dabigatran has been researched along with zithromax in 2 studies

Compound Research Comparison

Studies
(dabigatran)		Trials
(dabigatran)		Recent Studies (post-2010)
(dabigatran)		Studies
(zithromax)		Trials
(zithromax)		Recent Studies (post-2010) (zithromax)
3,8872613,4906,9641,2633,790

Protein Interaction Comparison

ProteinTaxonomydabigatran (IC50)zithromax (IC50)
30S ribosomal protein S6Escherichia coli K-120.3
30S ribosomal protein S7Escherichia coli K-120.3
50S ribosomal protein L15Escherichia coli K-120.3
50S ribosomal protein L10Escherichia coli K-120.3
50S ribosomal protein L11Escherichia coli K-120.3
50S ribosomal protein L7/L12Escherichia coli K-120.3
50S ribosomal protein L19Escherichia coli K-120.3
50S ribosomal protein L1Escherichia coli K-120.3
50S ribosomal protein L20Escherichia coli K-120.3
50S ribosomal protein L27Escherichia coli K-120.3
50S ribosomal protein L28Escherichia coli K-120.3
50S ribosomal protein L29Escherichia coli K-120.3
50S ribosomal protein L31Escherichia coli K-120.3
50S ribosomal protein L31 type BEscherichia coli K-120.3
50S ribosomal protein L32Escherichia coli K-120.3
50S ribosomal protein L33Escherichia coli K-120.3
50S ribosomal protein L34Escherichia coli K-120.3
50S ribosomal protein L35Escherichia coli K-120.3
50S ribosomal protein L36Escherichia coli K-120.3
30S ribosomal protein S10Escherichia coli K-120.3
30S ribosomal protein S11Escherichia coli K-120.3
30S ribosomal protein S12Escherichia coli K-120.3
30S ribosomal protein S13Escherichia coli K-120.3
30S ribosomal protein S16Escherichia coli K-120.3
30S ribosomal protein S18Escherichia coli K-120.3
30S ribosomal protein S19Escherichia coli K-120.3
30S ribosomal protein S20Escherichia coli K-120.3
30S ribosomal protein S2Escherichia coli K-120.3
30S ribosomal protein S3Escherichia coli K-120.3
30S ribosomal protein S4Escherichia coli K-120.3
30S ribosomal protein S5Escherichia coli K-120.3
30S ribosomal protein S8Escherichia coli K-120.3
30S ribosomal protein S9Escherichia coli K-120.3
50S ribosomal protein L13Escherichia coli K-120.3
50S ribosomal protein L14Escherichia coli K-120.3
50S ribosomal protein L16Escherichia coli K-120.3
50S ribosomal protein L23Escherichia coli K-120.3
30S ribosomal protein S15Escherichia coli K-120.3
50S ribosomal protein L17Escherichia coli K-120.3
50S ribosomal protein L21Escherichia coli K-120.3
50S ribosomal protein L30Escherichia coli K-120.3
50S ribosomal protein L6Escherichia coli K-120.3
30S ribosomal protein S14Escherichia coli K-120.3
30S ribosomal protein S17Escherichia coli K-120.3
30S ribosomal protein S1Escherichia coli K-120.3
50S ribosomal protein L18Escherichia coli K-120.3
50S ribosomal protein L2Escherichia coli K-120.3
50S ribosomal protein L3Escherichia coli K-120.3
50S ribosomal protein L24Escherichia coli K-120.3
50S ribosomal protein L4Escherichia coli K-120.3
50S ribosomal protein L22Escherichia coli K-120.3
50S ribosomal protein L5Escherichia coli K-120.3
30S ribosomal protein S21Escherichia coli K-120.3
50S ribosomal protein L25Escherichia coli K-120.3
50S ribosomal protein L36 2Escherichia coli K-120.3

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Carrier, M; Clark, EG; Garg, AX; Harel, Z; Hill, K; Hundemer, GL; Knoll, G; McArthur, E; Rhodes, E; Sood, MM; Sucha, E1
Chukhliaev, PV; Garbuzov, AA; Khavkina, DA; Ploskireva, AA; Ruzhentsova, TA1

Other Studies

2 other study(ies) available for dabigatran and zithromax

ArticleYear
Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants.
    JAMA internal medicine, 2020, 08-01, Volume: 180, Issue:8

    Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban

2020
[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients].
    Voprosy virusologii, 2021, 03-07, Volume: 66, Issue:1

    Topics: Acetylcysteine; Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Atrial Fibrillation; Azithromycin; Cohort Studies; Comorbidity; Coronary Disease; COVID-19; COVID-19 Drug Treatment; Dabigatran; Disseminated Intravascular Coagulation; Female; Humans; Hypertension; Indoles; Interferon alpha-2; Intracranial Arteriosclerosis; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; SARS-CoV-2; Severity of Illness Index; Survival Analysis

2021